Tonix制药控股 TNXP 深 沪
交易中 03-31 09:46:13 美东时间
12.28
+0.250
+2.08%
华盛通- 最 高12.28
- 今 开12.19
- 成交量 1.98万股
- 最 低 12.16
- 昨 收 12.03
- 总市值 1.57亿
- 52周最高 69.97
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 11.6028
- 委 比 -95.12%
- 总股本 1278.81万
- 历史最高 13440000000.00
- 量 比 14.28
- 振 幅 1.00%
- 历史最低 11.6028
- 每 手 1
- 风险率 10.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - March 30 ...
03-28 03:00
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Tonix Pharmaceuticals has initiated a Phase 1 study to evaluate TNX-1900, an intranasal oxytocin, for treating migraine and craniofacial pain. The study assesses its effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation models. TNX-1900 blocks CGRP release via oxytocin receptors in the trigeminal ganglion, targeting a distinct pathway compared to existing CGRP inhibitors. The study uses Laser Speckle Contrast...
03-26 11:00
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Serina Therapeutics (AMEX:SER) shares moved upwards by 94.5% to $2.49 d...
03-20 01:05
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals Holding Corp. will present an oral session and two posters on its preclinical immuno-oncology portfolio at AACR 2026 in San Diego. The oral presentation on TFF2 deficiency's role in tumor progression is led by Shuang Li and Timothy Wang, with Tonix's Seth Lederman and Bruce Daugherty as co-authors. The first poster on anti-BTLA antibodies is presented by Daugherty, while the second poster on TNX-1700 pharmacokinetics in anim...
03-17 20:35
财报速睇 | Tonix制药控股 2025财年Q4营收0.05亿美元，同比增长108.8%；归母净利润亏损0.47亿美元，同比亏损扩大112.2%
华盛资讯3月13日讯，Tonix制药控股公布2025财年Q4业绩，公司Q4营收0.05亿美元，同比增长108.8%，归母净利润亏损0.47亿美元，同比亏损扩大112.2%。
03-13 18:32
财报速睇 | Tonix制药控股 2025财年年度营收0.13亿美元，同比增长29.8%；归母净利润亏损1.24亿美元，同比亏损缩窄4.6%
华盛资讯3月13日讯，Tonix制药控股公布2025财年年度业绩，公司年度营收0.13亿美元，同比增长29.8%，归母净利润亏损1.24亿美元，同比亏损缩窄4.6%。
03-13 07:32
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data
Tonix Pharma ( ($TNXP) ) just unveiled an update. On March 10, 2026, Tonix Phar...
03-10 20:27
Tonix Pharma Announces Two Oral Presentations On TONMYATM, Investigated As TNX-102 SL, At 8th International Congress On Controversies In Fibromyalgia
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with
03-10 20:15
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
[Tonix Pharmaceuticals has launched TONMYA, the first new FDA-approved medication for fibromyalgia in over 15 years. Clinical trials showed rapid pain relief starting on Day 2, with significant improvements in symptoms. The drug demonstrated a favorable benefit-risk profile with a low rate of adverse events. TONMYA addresses a critical unmet need for fibromyalgia patients.]
03-10 12:00
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators signaling short-term weakness.
03-03 20:04
